We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+13.95%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.96B
AUM Growth
-$393M
Cap. Flow
-$554M
Cap. Flow %
-28.28%
Top 10 Hldgs %
32.05%
Holding
103
New
18
Increased
14
Reduced
37
Closed
22
Avg Time Held
1.1 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$49.4M
2
HUM icon
Humana
HUM
+$46.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$26.7M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$26.1M
5
ORKA icon
Oruka Therapeutics
ORKA
+$24.6M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$61M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$53.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$50.4M
4
AVTR icon
Avantor
AVTR
+$45.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$45.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BSX icon
1
Boston Scientific
BSX
$64B
$80.6M 4.11%
962,000
-208,100
-18% -$16.4M
2022 Q1
10 quarters
DNTH icon
2
Dianthus Therapeutics
DNTH
$4.17B
$79.9M 4.07%
2,917,231
– –
2023 Q3
4 quarters
ISRG icon
3
Intuitive Surgical
ISRG
$151B
$72.8M 3.71%
148,200
-96,800
-40% -$45.1M
2023 Q4
3 quarters
NTRA icon
4
Natera
NTRA
$58.3B
$70.6M 3.6%
556,400
-210,100
-27% -$24.1M
2020 Q3
16 quarters
CGON icon
5
CG Oncology
CGON
$5.48B
$62.5M 3.19%
1,656,000
+359,775
+28% +$12.6M
2024 Q1
2 quarters
ACHC icon
6
Acadia Healthcare
ACHC
$2.89B
$62.5M 3.19%
985,000
-135,000
-12% -$9.75M
2022 Q2
9 quarters
NBIX icon
7
Neurocrine Biosciences
NBIX
$13.9B
$53M 2.7%
460,000
-31,000
-6% -$4.25M
2020 Q4
15 quarters
UNH icon
8
UnitedHealth
UNH
$365B
$51.1M 2.61%
+87,400
New +$49.4M
2024 Q3
0 quarters
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$13.9B
$48M 2.45%
431,000
-113,500
-21% -$12.4M
2022 Q2
9 quarters
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.22B
$47.3M 2.41%
2,455,000
-880,000
-26% -$18.2M
2020 Q2
17 quarters
CATX icon
11
Perspective Therapeutics
CATX
$267M
$46M 2.35%
3,444,002
+406,334
+13% +$5.4M
2024 Q2
1 quarter
GKOS icon
12
Glaukos
GKOS
$9.77B
$44.9M 2.29%
344,900
+120,900
+54% +$15M
2024 Q1
2 quarters
IDYA icon
13
IDEAYA Biosciences
IDYA
$3.27B
$43.5M 2.22%
1,373,000
+256,000
+23% +$9.71M
2021 Q1
14 quarters
INSM icon
14
Insmed
INSM
$21.7B
$43.2M 2.2%
592,000
+162,000
+38% +$12M
2024 Q2
1 quarter
TMO icon
15
Thermo Fisher Scientific
TMO
$258B
$42.4M 2.16%
68,600
-11,400
-14% -$6.75M
2023 Q4
3 quarters
THC icon
16
Tenet Healthcare
THC
$22.2B
$42M 2.15%
253,000
-119,000
-32% -$18M
2022 Q4
7 quarters
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$1.5B
$41.8M 2.13%
752,000
-208,000
-22% -$10.6M
2021 Q3
12 quarters
HUM icon
18
Humana
HUM
$51.9B
$41.1M 2.1%
+129,700
New +$46.2M
2024 Q3
0 quarters
EXAS icon
19
DELISTED
Exact Sciences
EXAS
$40.1M 2.04%
588,000
+249,500
+74% +$14.1M
2024 Q2
1 quarter
ILMN icon
20
Illumina
ILMN
$40.5B
$38.1M 1.94%
292,000
-186,000
-39% -$22.9M
2024 Q1
2 quarters
ARVN icon
21
Arvinas
ARVN
$468M
$36.9M 1.88%
1,497,000
-1,490,845
-50% -$38.9M
2020 Q2
17 quarters
RVMD icon
22
Revolution Medicines
RVMD
$40.6B
$35.8M 1.83%
790,000
+35,000
+5% +$1.52M
2022 Q2
9 quarters
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$34.1M 1.74%
+2,132,000
New +$26.1M
2024 Q3
0 quarters
PHAT icon
24
Phathom Pharmaceuticals
PHAT
$607M
$32.6M 1.66%
1,804,493
+184,493
+11% +$2.58M
2021 Q4
11 quarters
XENE icon
25
Xenon Pharmaceuticals
XENE
$3.32B
$32.2M 1.64%
818,000
+64,000
+8% +$2.58M
2023 Q2
5 quarters
1
2 3 4 5

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q3 2024 Portfolio in Review

As of Q3 2024, Avidity Partners Management held 103 positions worth $1.96B, down 17% from $2.35B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Avidity Partners Management withdrew a net $554M in Q3 2024, closing 22 positions and reducing 37 holdings. Its most notable exit was Cigna, an estimated $61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in UnitedHealth worth $51.1M.

  • Avidity Partners Management's largest Q3 2024 buy was UnitedHealth: 87,400 shares worth $51.1M.
  • Avidity Partners Management added most to Oruka Therapeutics in Q3 2024, an estimated $24.6M increase.
  • Avidity Partners Management's biggest Q3 2024 reduction was Avantor, cutting an estimated $45.4M.
  • Avidity Partners Management fully exited Cigna in Q3 2024, selling an estimated $61M.
  • Avidity Partners Management's ten largest holdings make up 32% of its $1.96B portfolio in Q3 2024.
  • Avidity Partners Management opened 18 new positions and closed 22 in Q3 2024.
  • Avidity Partners Management's portfolio value fell 17% quarter-over-quarter to $1.96B.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.